Lots of interest in MRI for GCA diagnosis... but what about monitoring? Case series of 14 pts: MRI identified relapse prior to symptoms or inflammatory markers in 2 cases, including those on TCZ, which hides them More available in US context, noninvasive, & more structures https://t.co/pnrI9SEpll

• https://x.com/EBRheum/status/1983575532861083696/photo/1

Deucravacitinib (TYK2) in PsA from POETYK trials Improved ACR20 at wk16 (NNT ~5), less benefit for ACR70 (NNT ~20) Steady improvements during open label extension (all pts received drug) Would expect approval for PsA soon... where will this fit in your approach? @RheumNow https://t.co/325h2hf0AE

• https://x.com/EBRheum/status/1983566474951393426/photo/1
• https://x.com/EBRheum/status/1983566474951393426/photo/1

In early axSpA vs non-axSpA CBP, 2 year spinal x-ray progression was minimal in both groups. But on MRI, fat lesions increased significantly in axSpA (0.16 units/yr vs –0.02), with 15% having ≥3 lesions at 2 year vs 1% in non-axSpA. Fat lesions may signal early structural https://t.co/zvgU1Gt0po

• https://x.com/synovialjoints/status/1983564490311696460/photo/1

#ACR25 Clinical Preview by Prof Coates for use now: GLP-1 agonist & Diet Abstr#813 GIP/GLP-1 improved MSK pain Abstr#849 GLP-1 reduced risk of #MACE in PsA Abstr#2690 RCT = the degree of weight loss regardless specific dietary strategy determined benefit in PsA @RheumNow https://t.co/4jB0fFHosC

• https://x.com/Yuz6Yusof/status/1983564323973640562/photo/1
• https://x.com/Yuz6Yusof/status/1983564323973640562/photo/1
• https://x.com/Yuz6Yusof/status/1983564323973640562/photo/1

Observational study from VCRC AAV patinet, >70% had pulm involvement at some point As expected, nodules favor GPA (63% vs 12% MPA) & DAH favors MPA (61% vs 31%) More ILD in MPA (11% vs 1%) & more endobronchial in GPA (12% vs 2%) Helpful pearls! @RheumNow #ACR25 Abstr#0721 https://t.co/Iu5MdiTABR

• https://x.com/EBRheum/status/1983562335965905174/photo/1

#ACR25 Clinical Preview by Prof Coates to be applied tomorrow! GC #steroid burden & Mx Abstr#738 Survey of #GCA patients in US & EU: 3/4 were still on GC; mean 5.3mg/d Abstr#1526 International consensus of GC taper in #SLE is available & can be applied in clinic @RheumNow https://t.co/paw7NGjs4p

• https://x.com/Yuz6Yusof/status/1983560828860465223/photo/1
• https://x.com/Yuz6Yusof/status/1983560828860465223/photo/1

What exercise best for steroid-induced osteoporosis? Does it have to be weight bearing? Turns out anything helps - get out there and don’t let perfect be the enemy of good! Laura Coates in the #ACR25 meeting review @RheumNow https://t.co/VGH2rz3dzb

• https://x.com/drdavidliew/status/1983560241653645369/photo/1

Does diet matter in PsA? Randomized study comparing advice, DASH low calorie, Mediterranean diet Seems that weight loss corresponds better with benefit than diet. BMI reduction remains focus in PsA Laura Coates #ACR25 meeting review @RheumNow https://t.co/CqR25sJdDc

• https://x.com/drdavidliew/status/1983559618363281849/photo/1

This prospective study from Brazil evaluated the effect of RHZ vax in SSc pts SSc pts had ⬆️rates of seroconversion mean titers ⬆️ from BL Local rxs ⬇️ in SSc pts Systemic rxns comparable among the 2 grps interesting data. longterm studies still needed #ACR25 @RheumNow Abs2653 https://t.co/wJqpPrAHKG

• https://x.com/RHEUMarampa/status/1983559370366664781/photo/1
• https://x.com/RHEUMarampa/status/1983559370366664781/photo/1
• https://x.com/RHEUMarampa/status/1983559370366664781/photo/1

Trends in Translational Abstracts content this year by Tomas Mustelin in the “Abstracts that Will shape research in the near Future” Year in Preview session @RheumNow #ACR25 https://t.co/i5CA8cxHeQ

• https://x.com/AurelieRheumo/status/1983558386076840086/photo/1

Thank you @drdavidliew & @DrLauraCoates ❤️ for highlighting our work. Super-responders (some were IS-Free) do exist with rituximab in #SLE Abstr#1525 @RheumNow https://t.co/S4mMAYInfT

• https://twitter.com/drdavidliew/status/1983555936657854811

#ACR25 Clinical Preview by Prof Coates to be applied tomorrow! Early Tx Abstr#1677 First-line TNFi for 12-mth vs step-up = better outcomes at 5-Yr Abstr#2662 Target emulation trial = No differences in hospitalization, death/transplant RTX vs TNFi, ABA, JAK, IL-6i @RheumNow https://t.co/yostJyc5T9

• https://x.com/Yuz6Yusof/status/1983557041424908523/photo/1
• https://x.com/Yuz6Yusof/status/1983557041424908523/photo/1

New biomarkers in axSpA. In early axSpA (DESIR cohort), higher baseline Phospholipid transfer protein (PLTP) activity was linked to sacroiliac radiographic progression over 5 years. Lower zonulin and lipopolysaccharides (LPS) levels also associated with progression. Highlights https://t.co/1uBtR4QA97

• https://x.com/synovialjoints/status/1983556936080507088/photo/1

@Yuz6Yusof gets a shout out from Laura Coates in the #ACR25 meeting review for his work on rituximab super-responders in SLE @RheumNow https://t.co/EKUgmENesX

• https://x.com/drdavidliew/status/1983555936657854811/photo/1
• https://x.com/drdavidliew/status/1983555936657854811/photo/1

Year in Preview SLE: 52% subtherapeutic on weight based HCQ dosing Precision prescribing needed, more so for CKD @RheumNow #ACR25 Abstract 1722 https://t.co/8WqorQ1xJx

• https://x.com/JihaRheum/status/1983555467344310342/photo/1